• Overall, the incidence of recurrent VTE and stroke was low in morbidly obese patients who were prescribed apixaban, rivaroxaban, or warfarin; including those with BMI ≥50 kg/m²
  • In patients with VTE, no significant differences were observed between the DOAC and warfarin cohorts in bleeding events, including major bleeding